Genetic determinants of anticancer drug activity: Towards a global approach to personalized cancer medicine

Expert Review of Molecular Diagnostics

Volumn 11, Issue 6, 2011, Pages 567-577

  Picker, Alexander ^a   Jackson, David B ^a  

^a LIFE Biosystems GmbH   (Germany)

Author keywords

biomarker; clinical information; nonresponders; oncology; predictive medicine; targeted therapy

Indexed keywords

ABC TRANSPORTER; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; BINDING PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CETUXIMAB; CRIZOTINIB; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OROSOMUCOID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SUNITINIB; TRASTUZUMAB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; IMMUNOREACTIVITY; INTESTINE ABSORPTION; INTESTINE CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROTEIN EXPRESSION; RASH; RECEPTOR DOWN REGULATION; REVIEW; TUMOR REGRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PATIENT COMPLIANCE; POLYMORPHISM, GENETIC;

EID: 79960259254     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.45     Document Type: Review

References (53)

1. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64(24), 9139-9143 (2004) (Pubitemid 39665528)
2. Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 8(2), 129-138 (2008) (Pubitemid 351411549)
3. McKibbin T, Zhao W, Tagen M et al. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. Eur. J. Cancer 46(11), 2045-2051 (2010)
4. Agero AL, Dusza SW, Benvenuto- Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol. 55(4), 657-670 (2006) (Pubitemid 44436627)
5. Saltz L, Rubin MS, Hochster H et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin. Cancer Res. 7, 3766S (2001) (Abstract 559)
6. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007) (Pubitemid 46572540)
7. Judson I, Ma P, Peng B et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumor: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55, 379-386 (2005) (Pubitemid 40379262)
8. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44, 879-894 (2005) (Pubitemid 41252840)
9. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12), 3739-3745 (2004) (Pubitemid 39564452)
10. Hu S, Franke RM, Filipski KK et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 14(10), 3141-3148 (2008)
11. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104, 3739-3745 (2004) (Pubitemid 39564452)
12. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 106(3), 1133-1134 (2005)
13. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther. 83(2), 258-264 (2008)
14. Kim DH, Sriharsha L, Xu W et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 15(14), 4750-4758 (2009)
15. Takahashi N, Miura M, Scott SA et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet. 55(11), 731-737 (2010)
16. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587(2-3), 318-325 (2002) (Pubitemid 34655800)
17. Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112(5), 2024-2027 (2008)
18. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, Qian SX. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol. 28(1), 265-269 (2011)
19. Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of a1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the abl inhibitor STI571. J. Natl Cancer Inst. 92(20), 1641-1650 (2000)
20. Gschwind HP, Pfaar U, Waldmeier F et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 33, 1503-1512 (2005) (Pubitemid 41323999)
21. Nebot N, Crettol S, D'Esposito F, Tattam B, Hibbs DE, Murray M. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br. J. Pharmacol. 161, 1059-1069 (2010)
22. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics 11(7), 1003-1010 (2010)
23. Kim SR, Sai K, Tanaka-Kagawa T et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab. Dispos. 35(10), 1865-1872 (2007) (Pubitemid 47481580)
24. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010)
25. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004) (Pubitemid 38720929)
26. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004) (Pubitemid 38637993)
27. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(28), 6829-6837 (2005)
28. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010)
29. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487 (2007) (Pubitemid 47530601)
30. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (Pubitemid 32743979)
31. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475 (2002)
32. Choi YL, Soda M, Yamashita Y et al.; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734-1739 (2010)
33. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61(12), 4744-4749 (2001) (Pubitemid 32691885)
34. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99(8), 628-638 (2007) (Pubitemid 47073544)
35. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737-744 (1996)
36. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28(43), 3801-3813 (2009)
37. Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem. 282(14), 10432-10440 (2007)
38. Jacobs B, De Roock W, Piessevaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 27(30), 5068-5074 (2009)
39. Nagy P, Friedlander E, Tanner M et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65, 473-482 (2005)
40. Regales L, Balak MN, Gong Y et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2(8), E810 (2007)
41. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65(23), 11118-11128 (2005) (Pubitemid 41713383)
42. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2- positive early breast cancer. Clin. Cancer Res. 13(4), 1198-1207 (2007) (Pubitemid 46424061)
43. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104(52), 20932-20937 (2007)
44. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008)
45. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009)
46. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968-972 (2010)
47. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010)
48. Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27(16), 2622-2629 (2009)
49. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145 (2007) (Pubitemid 47587019)
50. Li FH, Shen L, Li ZH et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J. Gastroenterol. 16(46), 5881-5888. (2010)
51. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004) (Pubitemid 39070849)
52. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011)
53. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010)